Technical analysis of Genmab A/S (GMAB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses.
Price Performance
| 1 month | +42.72% |
| 3 months | +84.11% |
| Year-to-date | +78.31% |
| 1 year | +90.96% |
| 3 years | +88.79% |
| 5 years | +18.21% |
| 10 years | +212.05% |
52-Week Range
| 52-week High | $59.97 |
| 52-week Low | $23.62 |
| Avg Volume (90d) | 3.4M |
Technical Indicators
| SMA 50 | $37.55 |
| SMA 200 | $30.61 |
| Beta | 0.74 |
| 30-day Volatility (annualised) | 83.7% |
| Price vs SMA 50 | +46.3% |
| Price vs SMA 200 | +79.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $30.80 | |
| 2026-01 | $32.63 | +5.9% |
| 2026-02 | $29.44 | -9.8% |
| 2026-03 | $26.83 | -8.9% |
| 2026-04 | $26.52 | -1.2% |
| 2026-05 | $26.33 | -0.7% |
| 2026-06 | $27.47 | +4.3% |
| 2026-07 | $28.87 | +5.1% |
| 2026-08 | $33.16 | +14.9% |
| 2026-09 | $35.67 | +7.6% |
| 2026-10 | $57.06 | +59.9% |
| 2026-11 | $54.92 | -3.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-05 | $0.36 | $1.20B |
| 2026-08-06 | $0.37 | $1.12B |
| 2026-05-07 | $0.15 | $906M |
| 2026-02-17 | $0.46 | $1.07B |
| 2025-11-06 | $0.48 | $1.01B |
| 2025-08-07 | $0.39 | $953M |
| 2025-05-08 | $0.23 | $755M |
Price
| Price | $55.52 (closing price, November 3, 2026) |
| Market Cap | $34.1B |
| Exchange | NASDAQ |
| Country | DK |
Valuation Ratios
| P/E Ratio | 43.75 |
| Price / Book | 5.77 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.89 |
| Current Ratio | 2.46 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 2.83 |